![](/wp-content/uploads/2019/10/sanofi-mylan-biocon-announcement.png)
$599
Mylan Faces Setback in Sanofi Bs-Glargine Lawsuit
According to new court documents, the presiding judge in the Sanofi v. Mylan glargine lawsuit has denied Mylan’s request to rule two Lantus formulation patents invalid. The trial to settle the ongoing patent dispute is scheduled to start on December 2, 2019. Below, FENIX provides thoughts on the judge’s ruling and the potential impact on the Mylan/Biocon bs-glargine US launch timeline.